-+ 0.00%
-+ 0.00%
-+ 0.00%

Wedbush Upgrades Zentalis Pharmaceuticals to Outperform, Raises Price Target to $6

Benzinga·11/10/2026 15:13:08
Listen to the news
Wedbush analyst Robert Driscoll upgrades Zentalis Pharmaceuticals (NASDAQ:ZNTL) from Neutral to Outperform and raises the price target from $5 to $6.